Hair growth after using Herbodaya hair oil

A Randomized comparative clinical end point study to assess the Efficacy and safety of Herbodaya Bringa Hair oil and Shikaka Hair Wash in hair regrowth in male and female subjects with hair loss disorder

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/12/016730

Enrollment

Registered

2018-12-19

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L648- Other androgenic alopecia

Interventions

Intervention1: Herbodaya Bringa Hair oil: To take 5-10ml of the hair oil and gently apply & massage the oil daily at night for a period of 12 weeks: 1. Bhringaraj â??prevents hairfall, strengthens ro

acts as a hair tonic 8. Ponnanganni â??nourishes the scalp 9. Magandi â??hair conditioner, colourant & coolant 10. Methi â?? rich source of iron, hair conditioner, balances pitha 11. Neem â??prevents

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects with hair loss disorders such as telogen effluvium (as first line therapy), chronic female pattern hair loss, Androgenetic Alopecia (Stage I â?? IV) 2. Subjects who are willing to give written informed consent

Exclusion criteria

Exclusion criteria: 1.Androgenetic alopecia (Stage V and beyond) 2.Evidence of dermatological disease as revealed by history, physical examination or laboratory assessment which may interfere with administration or assessment of study medication 3.Current use of dermatological drugs / preparations which may interfere with study evaluation. 4.Intolerance to any of ingredients of the formulation 5.Current alcohol or drug abuse 6.Subjects viewed by the investigator as not being able to complete the study. 7.Use of Hair product such as hair dyes, sprays, setting gels and restorers 8.Any procedures for hair enhancement and curling or straightening technique 9.Pregnant or breastfeeding women 10. Having abnormal thyroid profile.

Design outcomes

Primary

Measure	Time frame
1. Change in global photographic assessment for hair growth. 2. VAS- Visual analog scale. 3. Change in the investigator assessment score for Hair count in each visit from enrollment onwards after treating with IP. 4. Subjective Assessment by the subjects using diary card Evaluation technique. 5. Percentage of subjects responding to the therapy. 6. Acceptability of the treatment. 7. Global assessment for efficacy by Investigator and subjects. Timepoint: AT 4 weeks, 8 weeks and 12 weeks.	—

Measure

Time frame

1. Change in global photographic assessment for hair growth. 2. VAS- Visual analog scale. 3. Change in the investigator assessment score for Hair count in each visit from enrollment onwards after treating with IP. 4. Subjective Assessment by the subjects using diary card Evaluation technique. 5. Percentage of subjects responding to the therapy. 6. Acceptability of the treatment. 7. Global assessment for efficacy by Investigator and subjects. Timepoint: AT 4 weeks, 8 weeks and 12 weeks.

—

Secondary

Measure	Time frame
Frequency of adverse events measuredTimepoint: 4,8 and 12 weeks	—

Countries

India

Contacts

Public ContactRamesh Kannan

KI3, CRO

srkguruvarshan@gmail.com7708925866

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026